, Volume 67, Issue 14, pp 1999–2012

Nonclassical Aspects of Differential Vitamin D Receptor Activation

Implications for Survival in Patients With Chronic Kidney Disease
Current Opinion


The ‘classical’ effects of vitamin D receptor activator or agonist (VDRA) therapy for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease primarily involves suppressive effects on the parathyroid gland, and regulation of calcium and phosphorus absorption in the intestine and mobilisation in bone. Observational studies in haemodialysis patients report improved cardiovascular and all-cause survival among those receiving VDRA therapy compared with those not on VDRA therapy. Among VDRAs, the selective VDRA paricalcitol has been associated with greater survival than nonselective VDRAs, such as calcitriol (1,25-dihydroxyvitamin D3). The survival benefits of paricalcitol appear to be linked, at least in part, to ‘nonclassical’ actions of VDRAs, possibly through VDRA-mediated modulation of gene expression. In cardiovascular tissues, VDRAs are reported to have beneficial effects such as anti-inflammatory and antithrombotic effects, inhibition of vascular smooth muscle cell proliferation, inhibition of vascular calcification and stiffening, and regression of left ventricular hypertrophy. VDRAs are also reported to negatively regulate the renin-angiotensin system, which plays a key role in hypertension, myocardial infarction and stroke. The selective VDRAs, paricalcitol and maxacalcitol, are associated with direct protective effects on glomerular architecture and antiproteinuric effects in response to renal damage. Paricalcitol regulates several cardiovascular and renal parameters more favourably than nonselective VDRAs. Complex nonclassical effects, which are not clearly understood, possibly contribute to the improved survival seen with VDRAs, especially paricalcitol.


  1. 1.
    Anavekar NS, McMurray JJV, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285–95PubMedCrossRefGoogle Scholar
  2. 2.
    Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–305PubMedCrossRefGoogle Scholar
  3. 3.
    Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999; 56 Suppl. 73: S14–9CrossRefGoogle Scholar
  4. 4.
    Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31–8PubMedCrossRefGoogle Scholar
  5. 5.
    Rix M, Andreassen H, Eskildsen P, et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999; 56: 1084–93PubMedCrossRefGoogle Scholar
  6. 6.
    Martinez I, Saracho R, Montenegro J, et al. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11 Suppl. 3: 22–8PubMedCrossRefGoogle Scholar
  7. 7.
    Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006; 116: 2062–72PubMedCrossRefGoogle Scholar
  8. 8.
    Naveh-Many T, Marx R, Keshet E, et al. Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest 1990; 86: 1968–75PubMedCrossRefGoogle Scholar
  9. 9.
    Silver J, Russell J, Sherwood LM. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci 1985; 82: 4270–3PubMedCrossRefGoogle Scholar
  10. 10.
    Indridason OS, Quarles LD, for the Durham Renal Osteodystrophy Study Group. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int 2000; 57: 282–92PubMedCrossRefGoogle Scholar
  11. 11.
    Levine BS, Song M. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 1996; 7: 488–96PubMedGoogle Scholar
  12. 12.
    Andress DL. Vitamin D treatment in chronic kidney disease. Semin Dial 2005; 18: 315–21PubMedCrossRefGoogle Scholar
  13. 13.
    Hudson JQ. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies. Ann Pharmacother 2006; 40: 1584–93PubMedCrossRefGoogle Scholar
  14. 14.
    Brancaccio D, Bommer J, Coyne D. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies. Drugs 2007; 67(14): 1981–98PubMedCrossRefGoogle Scholar
  15. 15.
    Wu-Wong JR, Nakane M, Traylor L, et al. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs. Curr Opin Invest Drug 2005; 6: 245–54Google Scholar
  16. 16.
    Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8–28PubMedCrossRefGoogle Scholar
  17. 17.
    Issa LL, Leong GM, Sutherland RL, et al. Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J Bone Miner Res 2002; 17: 879–90PubMedCrossRefGoogle Scholar
  18. 18.
    Takeyama K-I, Masuhiro Y, Fuse H, et al. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol 1999; 19: 1049–55PubMedGoogle Scholar
  19. 19.
    Wu-Wong JR, Nakane M, Ma J, et al. Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 2006; 186: 20–8PubMedCrossRefGoogle Scholar
  20. 20.
    Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-nor-1,25-(OH)2D3 and 1α-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats. Kidney Int 2002; 62: 1277–84PubMedCrossRefGoogle Scholar
  21. 21.
    Slatopolsky E, Finch J, Ritter C, et al. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis 1998; 32 Suppl. 2: S40–7PubMedCrossRefGoogle Scholar
  22. 22.
    Nakane M, Ma J, Rose AE, et al. Differential effects of vitamin D analogs on calcium transport. J Steroid Biochem Mol Biol 2007; 103: 84–9PubMedCrossRefGoogle Scholar
  23. 23.
    Hirata M, Endo K, Katsumata K, et al. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action. Nephrol Dial Transplant 2002; 17 Suppl. 10: 41–5PubMedCrossRefGoogle Scholar
  24. 24.
    Hirata M, Katsumata K, Endo K, et al. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol Dial Transplant 2003 Sep; 18(9): 1770–6PubMedCrossRefGoogle Scholar
  25. 25.
    Akizawa T, Suzuki M, Akiba T, et al. Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients: one-year administration study. Nephrol Dial Transplant 2002; 17 Suppl. 10: 28–36PubMedCrossRefGoogle Scholar
  26. 26.
    Tamura S, Ueki K, Mashimo K, et al. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients. Clin Exp Nephrol 2005 Sep; 9(3): 238–43PubMedCrossRefGoogle Scholar
  27. 27.
    Martin KJ, Gonzalez EA. Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis 2001; 38 Suppl. 5: S34–40PubMedCrossRefGoogle Scholar
  28. 28.
    Goltzman D. Use of genetically modified mice to examine skeletal anabolic activity of vitamin D. J Steroid Biochem Mol Biol 2007; 103: 587–91PubMedCrossRefGoogle Scholar
  29. 29.
    Nakane M, Fey TA, Dixon DB, et al. Differential effects of vitamin D analogs on bone formation and resorption. J Steroid Biochem Mol Biol 2006; 98: 72–7PubMedCrossRefGoogle Scholar
  30. 30.
    Hirata M, Katsumata K, Masaki T, et al. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 1999 Dec; 56(6): 2040–7PubMedCrossRefGoogle Scholar
  31. 31.
    Joist HE, Ahya SN, Giles K, et al. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. Clin Nephrol 2006; 2006: 335–41Google Scholar
  32. 32.
    Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115–25PubMedCrossRefGoogle Scholar
  33. 33.
    Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771–80PubMedCrossRefGoogle Scholar
  34. 34.
    Young EW, Albert JM, Akiba T, et al. Vitamin D therapy and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS) [abstract]. J Am Soc Nephrol 2005; 16: 278AGoogle Scholar
  35. 35.
    Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003 Jul 31; 349(5): 446–56PubMedCrossRefGoogle Scholar
  36. 36.
    Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006 Nov; 70(10): 1858–65PubMedCrossRefGoogle Scholar
  37. 37.
    Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. Epub 2007 Aug 8Google Scholar
  38. 38.
    USRDS. United States Renal Data System. USRDS 2006 Annual Data Report, 2006 [online]. Available from URL: http://www.usrds.org/adr.htm [Accessed 2007 Sep 6]
  39. 39.
    Rivard A, Andres V. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases. Histol Histopathol 2000; 15: 557–71PubMedGoogle Scholar
  40. 40.
    Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695–701PubMedCrossRefGoogle Scholar
  41. 41.
    London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731–40PubMedCrossRefGoogle Scholar
  42. 42.
    Yildiz A, Memisoglu E, Oflaz H, et al. Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic haemodialysis patients. Nephrol Dial Transplant 2005; 20: 760–7PubMedCrossRefGoogle Scholar
  43. 43.
    Wilson PWF, Kauppila LI, O’Donnell C, et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001; 103: 1529–34PubMedCrossRefGoogle Scholar
  44. 44.
    Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938–42PubMedCrossRefGoogle Scholar
  45. 45.
    Zimmerman J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648–58CrossRefGoogle Scholar
  46. 46.
    London GM, Geurin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613–20PubMedCrossRefGoogle Scholar
  47. 47.
    Chen NX, Duan D, O’Neill KD, et al. The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney Int 2006; 70: 1046–53PubMedCrossRefGoogle Scholar
  48. 48.
    Chen NX, O’Neill KD, Duan D, et al. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002; 62: 1724–31PubMedCrossRefGoogle Scholar
  49. 49.
    Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: 10–7CrossRefGoogle Scholar
  50. 50.
    Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2005; 69: 33–43CrossRefGoogle Scholar
  51. 51.
    Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959–64PubMedCrossRefGoogle Scholar
  52. 52.
    Mitsuhashi T, Morris Jr RC, Ives HE. 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest 1991; 87: 1889–95PubMedCrossRefGoogle Scholar
  53. 53.
    Merke J, Milde P, Lewicka S, et al. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3: studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 1989; 83: 1903–15PubMedCrossRefGoogle Scholar
  54. 54.
    Cardus A, Gallego C, Muray S, et al. Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells [in Spanish]. Nefrologia 2003; 23 Suppl. 2: 117–21PubMedGoogle Scholar
  55. 55.
    Cardus A, Parisi E, Gallego C, et al. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 2006; 69: 1377–84PubMedGoogle Scholar
  56. 56.
    Wu-Wong JR, Noonan W, Ma J, et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther 2006; 318: 90–8PubMedCrossRefGoogle Scholar
  57. 57.
    Cardus A, Panizo S, Parisi E, et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860–6PubMedCrossRefGoogle Scholar
  58. 58.
    Wanner C, Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002; 17 Suppl. 8: 29–32PubMedCrossRefGoogle Scholar
  59. 59.
    Timms PM, Mannan N, Hitman GA, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders. Q J Med 2002; 95: 787–96CrossRefGoogle Scholar
  60. 60.
    Jung HH, Kim S-W, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant 2006; 21: 1915–20PubMedCrossRefGoogle Scholar
  61. 61.
    Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747–54PubMedCrossRefGoogle Scholar
  62. 62.
    Watson KE, Parhami F, Shin V, et al. Fibronectin and collagen I matrixes promote calcification of vascular cells in vitro, whereas collagen IV matrix is inhibitory. Arterioscler Thromb Vasc Biol 1998; 18: 1964–71PubMedCrossRefGoogle Scholar
  63. 63.
    Parhami F, Basseri B, Hwang J, et al. High-density lipoprotein regulates calcification of vascular cells. Circ Res 2002; 91: 570–6PubMedCrossRefGoogle Scholar
  64. 64.
    Tintut Y, Patel J, Parhami F, et al. Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000; 102: 2636–42PubMedCrossRefGoogle Scholar
  65. 65.
    Watson KE, Bostrom K, Ravindranath R, et al. TGF-β1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 1994; 93: 2106–13PubMedCrossRefGoogle Scholar
  66. 66.
    Bostrom K, Watson KE, Horn S, et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91: 1800–9PubMedCrossRefGoogle Scholar
  67. 67.
    Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78–81PubMedCrossRefGoogle Scholar
  68. 68.
    Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002; 196: 1047–55PubMedCrossRefGoogle Scholar
  69. 69.
    Bellows CG, Reimers SM, Heersche JNM. Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3. Cell Tissue Res 1999; 297: 249–59PubMedCrossRefGoogle Scholar
  70. 70.
    Drissi H, Pouliot A, Koolloos C, et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 2002; 274: 323–33PubMedCrossRefGoogle Scholar
  71. 71.
    Panichi V, De Pietro S, Andreini B, et al. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int 1998; 54: 1463–9PubMedCrossRefGoogle Scholar
  72. 72.
    Turk S, Akbulut M, Yildiz A, et al. Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron 2002; 90: 188–94PubMedCrossRefGoogle Scholar
  73. 73.
    Virdi AS, Cook LJ, Oreffo RO, et al. Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic lines. Cell Mol Biol 1998; 44: 1237–46PubMedGoogle Scholar
  74. 74.
    Abe H, Iehara N, Utsunomiya K, et al. A vitamin D analog regulates mesangial cell smooth muscle phenotypes in a transforming growth factor-β type II receptor-mediated manner. J Biol Chem 1999; 274: 20874–8PubMedCrossRefGoogle Scholar
  75. 75.
    Fraser JD, Otawara Y, Price PA. 1,25-dihydroxyvitamin D3 stimulates the synthesis of matrix γ-carboxyglutamic acid protein by osteosarcoma cells: mutually exclusive expression of vitamin K-dependent bone proteins by clonal osteoblastic cell lines. J Biol Chem 1988; 263: 911–6PubMedGoogle Scholar
  76. 76.
    Mizobuchi M, Finch JL, Martin DR, et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. Epub 2007 Jun 27Google Scholar
  77. 77.
    Ohsawa M, Koyama T, Yamamoto K, et al. 1α,25-Dihydroxyvitamin D3 and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation 2000; 102: 2867–72PubMedCrossRefGoogle Scholar
  78. 78.
    Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004; 279: 35798–802PubMedCrossRefGoogle Scholar
  79. 79.
    Petrie MS, Harrell TE, Schwartz GG, et al. Production of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells: differential responses to calcitriol and paricalcitol. J Thromb Haemost 2004; 2: 2266–7PubMedCrossRefGoogle Scholar
  80. 80.
    Nordt TK, Peter K, Ruef J, et al. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 1999; 82 Suppl.: 14–8PubMedGoogle Scholar
  81. 81.
    Nitta K, Akiba T, Uchida K, et al. Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 2004; 27: 47–52PubMedCrossRefGoogle Scholar
  82. 82.
    Patrianakos AP, Parthenakis FI, Karakitsos D, et al. Relation of proximal aorta stiffness to left ventricular diastolic function in patients with end-stage renal disease. J Am Soc Echocardiogr 2007; 20: 314–23PubMedCrossRefGoogle Scholar
  83. 83.
    Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 103: 987–92PubMedCrossRefGoogle Scholar
  84. 84.
    London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12: 2759–67PubMedGoogle Scholar
  85. 85.
    Noonan W, Ma J, Dixon D, et al. Differential effects of vitamin D analogs on aortic calcification and pulse wave velocity in uremic rats [abstract no. SP355]. XLIII European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress; 2006 Jul 15–18; GlasgowGoogle Scholar
  86. 86.
    Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005 Sep; 16(9): 2778–88PubMedCrossRefGoogle Scholar
  87. 87.
    Thadhani RAJ, Achinger S, Shivalingappa V, et al. Paricalcitol and cardiac structure and function in animals and humans [abstract no. TH-FC155]. J Am Soc Nephrol 2006; 17: 21ACrossRefGoogle Scholar
  88. 88.
    Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229–38PubMedGoogle Scholar
  89. 89.
    Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: 125–32CrossRefGoogle Scholar
  90. 90.
    Wu-Wong JR, Nakane M, Ruan X, et al. The role of vitamin D receptor in regulating renin [abstract no. SO35]. XLIII European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress; 2005 Jun 4–7; IstanbulGoogle Scholar
  91. 91.
    Nakane M, Fey TA, Droz BA, et al. Effect of paricalcitol on renal renin mRNA expression in vitamin D-deficient rats [abstract no. TH-PO288]. American Society of Nephrology (ASN) 38th Renal Week Meeting; 2005 Nov 8–13; Philadelphia (PA)Google Scholar
  92. 92.
    Pan L, Black TA, Shi Q, et al. Critical roles of a cyclic AMP responsive element and an E-box in regulation of mouse renin gene expression. J Biol Chem 2001; 276: 45530–8PubMedCrossRefGoogle Scholar
  93. 93.
    Tian J, Liu Y, Williams LA, et al. Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 2007; 22: 321–8PubMedCrossRefGoogle Scholar
  94. 94.
    Matthias S, Busch R, Merke J, et al. Effects of 1,25(OH)2D3 on compensatory renal growth in the growing rat. Kidney Int 1991; 40: 212–8PubMedCrossRefGoogle Scholar
  95. 95.
    Weih M, Orth S, Weinreich T, et al. Inhibition of growth by calcitriol in a proximal tubular cell line (OK). Nephrol Dial Transplant 1994; 9: 1390–4PubMedGoogle Scholar
  96. 96.
    Weinreich T, Merke J, Schonermark M, et al. Actions of 1,25-dihydroxyvitamin D3 on human mesangial cells. Am J Kidney Dis 1991; 18: 359–66PubMedGoogle Scholar
  97. 97.
    Schwarz U, Amann K, Orth SR, et al. Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrec-tomized rats. Kidney Int 1998; 53: 1696–705PubMedCrossRefGoogle Scholar
  98. 98.
    Tan X, Li YC, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17: 3382–93PubMedCrossRefGoogle Scholar
  99. 99.
    Sanai T, Tokumoto M, Hirano T, et al. Different effects of 22-oxacalcitriol and calcitriol on the course of experimental chronic renal failure. J Lab Clin Med 2002; 140: 242–9PubMedCrossRefGoogle Scholar
  100. 100.
    Keane WF, Eknoyan G, for the National Kidney Foundation PARADE Committee. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33: 1001–10CrossRefGoogle Scholar
  101. 101.
    Foley RN, Parfrey PS, Harnett JD, et al. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 1996; 7: 728–36PubMedGoogle Scholar
  102. 102.
    De Zeeuw D, Remuzzi G, Parving H-H, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309–20PubMedCrossRefGoogle Scholar
  103. 103.
    Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823–8PubMedCrossRefGoogle Scholar
  104. 104.
    Maenpaa PH, Vaisanen S, Jaaskelainen T, et al. Vitamin D(3) analogs (MC 1288, KH 1060, EB 1089, GS 1558, and CB 1093): studies on their mechanism of action. Steroids 2001; 66(3–5): 23–5Google Scholar
  105. 105.
    Imanishi Y, Inaba M, Seki H, et al. Increased biological potency of hexaflourinated analogs of 1,25-dihydroxyvitamin D3 on bovine parathyroid cells. J Steroid Biochem Mol Biol 1999; 70(4): 243–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Department of MedicineUniversity of WashingtonSeattleUSA

Personalised recommendations